Explore Cutting-Edge ASI Clinical Studies
This clinical study evaluates the performance of ASI’s computer-aided karyotyping software in routine chromosome analysis, demonstrating substantial improvements in chromosome placement accuracy and workflow efficiency while reinforcing the essential role of expert cytogeneticists in diagnostic interpretation.
The results show a four-fold improvement in chromosome classification accuracy and a 52% reduction in analysis time, highlighting the value of AI-assisted karyotyping for routine and complex cytogenetic workflows.
The findings demonstrate how integrated cytogenetic, genetic, and functional analyses can support accurate diagnosis, helping to rule out Fanconi Anemia and guide appropriate clinical management in complex cases.
A recent study highlights the importance of multimodal cytogenetic and molecular approaches in detecting complex structural variants.
Results show over 99% correlation between dedicated FISH analysis and IMS review, supporting reliable integration of FISH images into digital pathology workflows.
The study demonstrates high concordance between digital and manual assessments, highlighting the potential of combined H&E and IF WSI review to improve diagnostic insight and efficiency.
This multicenter pilot study assesses a new AI-based metaphase finder designed to improve detection during slide scanning. The results demonstrate increased metaphase identification and reduced capture of non-metaphase material, enhancing efficiency in karyotyping workflows.
This study evaluates an AI-based scanner-agnostic add-on for automated karyotyping that integrates with existing imaging systems. Results show a significant reduction in metaphase analysis time, supporting faster and more efficient cytogenetic workflows.
A new breast cancer study demonstrates how ASI’s HiPath Pro platform support AI-driven predictive oncology through high-quality digital pathology imaging.
ASI’s second abstract presented at ECP 2025 demonstrates strong agreement between manual and computational scoring of Ki-67 in breast cancer. The study validates ASI’s AI-powered quantification tools as a reliable complement to routine pathology assessment.
This study shows that computer-aided scoring provides a reliable and reproducible method for assessing HER2 immunostaining in breast cancer with high intra-tumoral heterogeneity.
Mendel Laboratories in Mexico used ASI’s HiBand system to demonstrate the efficiency gains of AI-powered karyotyping – significantly reducing analysis time for the analysis of both normal and abnormal cases.